APPENDICES. A systematic review and economic model of the ...

202
Appendix 12
Study Intervention Participants Outcomes
Core symptoms
Not reported
Reference
Ahmann et al., 1993 35
Co-existent problems
Not reported
Arm 1
MPH
0.3 mg/kg; administered three times daily
(Individual administering medication not
reported)
Source
AHRQ Report
Educational performance
Not reported
Inclusion criteria
At least three of the following criteria had to be met:
1. ACTeRS Attention Score = 25th percentile
2. ACTeRS Hyperactivity Score = 25th percentile
3. CTRS-28 Inattention/Passivity Scale two or more SD above the mean
4. CTRS-28 Hyperactivity Index two or more SD above the mean
5. CPRS-48 Hyperactivity Index two or more SD above the mean
In addition:
6. No history of seizures, mental retardation, Tourette’s syndrome or
other significant neurological history
Arm 2
MPH
0.5 mg/kg; administered three times daily
(Individual administering medication not
reported)
Setting
USA
(tertiary care clinic)
Psychological function
Not reported
Design
Crossover trial
Depression or anxiety
Not reported
Quality of life
Not reported
Diagnostic criteria
DSM-III-R
Number
Total randomised = 234 (male = 189)
Total withdrawals = 28
Arm 3
Placebo
Administered three times daily
(Individual administering medication not
reported)
Duration
Each treatment was
given for 7 days over a
4-week period.
Adverse events
Barkley Side Effects
Questionnaire (BSEQ)
Reasons for withdrawals:
Adverse events: n = 4
Additional outcomes
Not reported
Purpose
To assess the frequency
of side-effects of Ritalin
therapy in children with
ADHD
Randomisation procedure:
Randomisation was conducted for MPH 0.3 mg/kg and placebo, and then
again after 2 weeks for MPH 0.5 mg/kg and placebo
Age
5–15 years (range)
IQ
Not reported
Co-morbid disorders
Not reported
Diagnostic subtypes
Not reported
Additional information
No relevant information reported